Download the white paper. In 1986, the first monoclonal antibody became licensed as a therapeutic drug–an event occurring nine years after the generation of the first monoclonal antibody (mAb) [1]. The journey of how monoclonal antibodies…
Read More
Our Custom Antibody Services Play a Key Role in Cancer Biomarker Study
ProSci’s custom antibody service played a crucial role in the recent study conducted by the Genome Protection and Roswell Park Comprehensive Cancer Center titled “Cancer relevance of circulating antibodies against LINE-1 antigens in humans ”…
Read More
ProSci’s Custom Antibody Services Support Study Investigating Efficacy of Tau Antibodies
We’re thrilled to announce that Dr. Sigurdsson’s distinguished research team conducted a cutting-edge study on the efficacy and safety profile of sdAbs with the help of our scientists, who provide leading Custom Single Domain (VHH)…
Read More
Does Your Research Require High-Quality and Consistent Rabbit Recombinant Antibodies?
Download the white paper. Recombinant antibodies have revolutionized the field of research, offering a more specific, consistent, and high-quality alternative to traditional antibody development methods. ProSci offers a comprehensive suite of services for recombinant antibody…
Read More
Single Domain Antibodies: Unlocking the Potential of Targeted Therapeutics
Antibodies are an essential immune system component and play a vital role in disease diagnosis and treatment. In recent years, breakthroughs in the development of single-domain antibodies (sdAbs) have opened new possibilities in biotechnology and…
Read More
Enhance your Research with ProSci’s Polyclonal Antibody Services
What are Polyclonal Antibodies? Download the white paper. Polyclonal antibodies are a mixture of antibodies from multiple B-cell clones of a host animal that can recognize multiple epitopes on an antigen. Their unique binding characteristic…
Read More
Maximizing Your Success with ProSci’s Custom Monoclonal Antibody Services
The monoclonal antibody market is expected to reach $524.68 billion by 2030. This highlights the growing demand for monoclonal antibodies in biomedical research, diagnostics, and therapeutic development. Monoclonal antibodies (mAbs) have revolutionized medicine by providing…
Read More
